Pulmatrix (NASDAQ:PULM – Get Free Report) announced its earnings results on Friday. The biotechnology company reported ($0.54) earnings per share for the quarter, Zacks reports. Pulmatrix had a negative return on equity of 45.97% and a negative net margin of 96.51%.
Pulmatrix Price Performance
NASDAQ:PULM opened at $7.47 on Friday. The firm’s fifty day moving average price is $7.47 and its 200 day moving average price is $5.17. Pulmatrix has a 1-year low of $1.56 and a 1-year high of $10.40. The firm has a market cap of $27.27 million, a price-to-earnings ratio of -2.83 and a beta of 1.66.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on shares of Pulmatrix in a report on Sunday, January 5th. They issued a “hold” rating on the stock.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Recommended Stories
- Five stocks we like better than Pulmatrix
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- 3 Small Caps With Big Return Potential
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
- Roth IRA Calculator: Calculate Your Potential Returns
- MarketBeat Week in Review – 03/17 – 03/21
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
